6 -Identification of new therapeutic targets and preclinical evaluation of new compounds for the treatment of sarcomas. We are testing in vitro and in vivo several new compounds on soft tissue sarcoma cell lines to obtain preclinical data for future clinical trials. mtor inhibitors: We are currently testing mtorc1 and mtorc2 inhibitors on myxoid liposarcomas and Ewing s sarcomas and exploring the mechanisms by which they are effective. We are interested in dual PI3K/mTOR inhibitors and MEK inhibitors (everolimus +MEK162) CDK s inhibitors: We are currently testing these inhibitors in several soft tissue sarcomas. Glucose inhibitors for the treatment of rhabdomyosarcomas (Collaboration with Cristina Muñoz Pinedo from the Cell Death Regulation Group)

te: Consider Clinical Trials as treatment options for eligible patients. Referral to a center with both pediatric oncology and orthopedic surgery is essential. CLINICAL EVALUATION This practice algorithm

PharmaMar announces new advances in oncology at ASCO 2015 for its compounds YONDELIS and PM1183 in small cell lung cancer, soft tissue sarcoma, and mesothelioma Compelling clinical activity of PM1183 in

CALL FOR PARTNERSHIP MULTIPLI PROGRAM I. Introduction The MULTIPLI program, coordinated by Inserm (the French National Institute of Health and Medical Research) and the Cancer Institute of the French National

Department of BioScience Technology Chung Yuan Christian University 2015/08/13 Cancer Cells Cancer, the 1st leading cause of death, is an example of a disease that arises from abnormalities in cell function

What is the reference cytotoxic regimen in advanced gastric cancer? Florian Lordick Professor of Oncology Director of the University Cancer Center Leipzig (UCCL) Germany What we know from clinical research.

TREATMENT UPDATE WWW.CANCERCARE.ORG The CancerCare Connect Booklet Series offers up-to-date, easy-to-read information on the latest treatments, managing side effects, and coping with cancer. To order free

Marbella (Spain), January 29th & 30th, 2015 Diagnostic and Therapeutic Colonoscopy for Colorectal Neoplasia in the 21st Century: Preliminary Program Thursday, January 29th 2015 15:45-16:00 Welcome to the

Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

FOUR-STAGE RESEARCH CAREER AT IDIBAPS Date: February 2014 Several studies aimed to define a European framework for research careers have converged in a four-stage research career framework which starts

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single

Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

Ching-Yao Yang, Yu-Wen Tien Division of General Surgery, Department of Surgery, National Taiwan University Hospital Oct-30-2010 Pancreatic NET have poorer prognosis when presence of liver metastases at

Conducting Phase 1 studies in Pediatric Oncology A model applicable to other disciplines? Sylvain Baruchel MD New Agent and Innovative Therapy Program Toronto Hospital For Sick Children MILESTONES IN PEDIATRIC

THE EHE FOUNDATION THE EHE RARE CANCER CHARITY (UK)* THE EHE RARE CANCER FOUNDATION (AUSTRALIA)* Fundraising and Research Objectives Thank you for taking the time to find and engage with our Fundraising

Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology

Understanding series LUNG CANCER: new treatment directions 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS What s New in lung cancer? Advancements...4 Changes in genes that

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the

Reporter s Guide to Multiple Myeloma Reporter s Guide to Multiple Myeloma 1 What is What causes treated? PHEM/DAT/0116/000 Reporter s Guide to Multiple Myeloma What is What causes treated? What is Multiple

ALLOS THERAPEUTICS, INC. 2000 ANNUAL REPORT Building an Oncology Franchise Allos is a product company that develops and commercializes small molecule oncology and cardiovascular drugs. Our lead product

DRAFT PROGRAMME Transbio Valencia event February 27th and 28th Field Study Best practices for company creation and development Workshop Housing & access to technologies for biotech companies Calendar February

Measles virotherapy for malignant mesothelioma Manish R. Patel, D.O. Assistant Professor of Medicine University of Minnesota June 25, 2011 Medical Treatment of Mesothelioma Majority of patients are not

Experience of a Pediatric Oncology Clinical Research Center in Brazil Antonio Sergio Petrilli, MD, PhD Children and adolescents Heterogeneous in many aspects 38% of Brazilian population (IBGE, 2000) 11,530

for lung cancer Outcomes in advanced lung cancer have seen meaningful improvement in the past decade thanks to new precision drug therapies. Because tumors usually develop resistance to the drugs, scientists